Oxygenta Pharmaceutical Limited, originally S S Organics Ltd, is a pharmaceutical company established in 1990, which transitioned to a limited company in 1993. The company specializes in manufacturing bulk drugs, focusing on anti-ulcerative and antibacterial medications. It also produces a range of new-generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs. The company operates a manufacturing plant in Medak, Andhra Pradesh.
Oxygenta engages in both contract manufacturing and its own production, notably producing Ciprofloxacin HCL for APL and manufacturing Pantaprozole Sodium and Gabapentine independently. Contract manufacturing, particularly with APL, is crucial for maintaining consistent income and covering operational expenses while the company works towards obtaining working capital limits from banks. After resuming commercial production in July 2015 following a fire incident, the company is currently stabilizing its manufacturing and marketing processes.
